官方服务：
资源简介：
FMD, AIX treatment agalsidase beta vs placebo in Fabry patients
应用场景：
创建时间：
2020-08-03
相关数据集
STARS_Phase2_加波沙朵治疗安格曼综合征随机对照试验数据
本数据集为STARS phase 2研究的补充表格数据，包含加波沙朵治疗安格曼综合征的多中心随机对照试验结果，涉及安全性、耐受性及探索性疗效终点分析，支持神经疾病药物研发及临床研究参考。 论文“The STARS phase 2 study: a randomized controlled trial of gaboxadol in Angelman syndrome”
海数据40
Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial
The study objective was to assess the effect of vutrisiran, an RNA interference therapeutic that reduces transthyretin (TTR) production, in patients with hereditary transthyretin (ATTRv) amyloidosis w
Mendeley Data2024-06-27 更新30
Supplementary materials: Confirmatory long-term efficacy and safety results of ataluren in patients with nmDMD from Study 041, an international, randomized, double-blind, placebo-controlled, phase III trial
These are peer-reviewed supplementary materials for the article 'Confirmatory long-term efficacy and safety results of ataluren in patients with nmDMD from Study 041, an international, randomized, dou
Figshare2025-08-22 更新10
Global Fabry Disease Treatment Market 2025 To 2034
Fabry Disease Treatment Market Size, Trends and Insights By Treatment (Enzyme Replacement Therapy (ERT), Chaperone Treatment, Substrate Reduction Therapy (SRT), Others), By Route of Administration (In
NIAID Data Ecosystem30
Plasma Migalastat PK Summary.
a Geometric mean (CV%) b Median (range) c Arithmetic mean (CV%) Plasma Migalastat PK Summary.
NIAID Data Ecosystem20
